Skip to content
OpenCapital
Get started

Recursion Pharmaceuticals, Inc. RXRX Q4 2025 Annual earnings

Reported February 25, 2026 · Before market open

Revenue$35.4MBeat by $10.8M
EPS-$0.21Beat by $0.07
Revenue estimate$24.5M
EPS estimate-$0.28

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$11.0M
EPS estimate-$0.25

Financials

Q4 2025

Income statement

See full
Revenue$35.5M+682%
Gross profit$21.3M—
Operating income-$108.3M+41.0%
Net income-$108.1M+39.6%
EPS (diluted)-$0.17+70.2%

Balance sheet

See full
Cash & equivalents$753.9M+25.0%
Total debt$96.3M-28.7%
Total equity$1.1B+9.3%
Total assets$1.5B+1.8%

Cash flow

See full
Operating cash flow-$46.1M+60.1%
CapEx$1.2M-4.2%
Free cash flow-$47.3M+59.5%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$2.13B-19.4%
Enterprise value$1.47B-32.3%
P/S28.5×-16.4×

Profitability

See full
Gross margin5%—
Operating margin-867.9%+61.4pp
Net margin-863.4%+91.3pp
FCF margin-506.5%-84.7pp

Returns & leverage

See full
Return on equity-59.5%-2.2pp
Debt / equity0.1×0.0×
Current ratio5.5×+1.7×

Segments

By product

See full
Operating revenue$35.4M+684%
Grant revenue$187.0K+434%

By segment

See full
Reportable Segment$35.5M+682%

By geography

See full
Other--100%

Versus estimates

Revenue

Q1 2026$6.3MMiss by $9.5M
Q4 2025$35.4MBeat by $10.8M
Q3 2025$5.2MMiss by $19.4MQ2 2025$19.1MMiss by $822.0KQ1 2025$14.7MBeat by $785.0KQ4 2024$4.5MMiss by $14.5M

Diluted EPS

Q1 2026-$0.22Beat by $0.08
Q4 2025-$0.21Beat by $0.07
Q3 2025-$0.36Beat by $0.02Q2 2025-$0.41Miss by $0.06Q1 2025-$0.50Miss by $0.06Q4 2024-$0.53Miss by $0.09

Ask the moment Recursion Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Recursion Pharmaceuticals, Inc. report Q4 2025 earnings?
Recursion Pharmaceuticals, Inc. (RXRX) reported Q4 2025 earnings on February 25, 2026 before market open.
What were Recursion Pharmaceuticals, Inc.'s Q4 2025 revenue and EPS?
Recursion Pharmaceuticals, Inc. reported revenue of $35.4M and eps of $-0.21 for Q4 2025.
Did Recursion Pharmaceuticals, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $24.5M by $10.8M. EPS beat the consensus estimate of $-0.28 by $0.07.
How did Recursion Pharmaceuticals, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 683.7% from $4.5M a year earlier and eps grew 60.4% from $-0.53.
Where can I find Recursion Pharmaceuticals, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001601830-26-000038) and the 10-K periodic report (0001601830-26-000039) directly on SEC EDGAR. The filing index links above go to sec.gov.